Form 4 for WGS GeneDx Holdings Corp.
Accepted 2025-07-11 00:00:00 ET · period of report 2025-07-09 · accession 0001415889-25-019666 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-07-11 | 2025-07-09 | WGS | Stueland Katherine | CEO, Dir | S - Sale | $93.00 | -3,220 | 1,720 | -65% | -$299.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2025-07-09 | S | D | 3,220 | $93.00 | 1,720 | D | — | — | (F2) Following the reported sales, in addition to the 1,720 shares of Class A common stock beneficially owned by the Reporting Person, the Reporting Person beneficially owned restricted stock units ("RSUs") representing contingent rights to receive up to an aggregate of 473,709 shares of Class A common stock and options to purchase up to an aggregate of 107,610 shares of Class A common stock, which RSUs and options vest according to their respective terms. |